 Breelyn Wilky
Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 16 | 2022 | 137 | 5.330 |
Why?
| | Soft Tissue Neoplasms | 8 | 2022 | 93 | 2.560 |
Why?
| | Fibromatosis, Aggressive | 4 | 2023 | 19 | 2.050 |
Why?
| | Immunotherapy | 10 | 2023 | 493 | 1.910 |
Why?
| | Sarcoma, Alveolar Soft Part | 2 | 2023 | 7 | 1.610 |
Why?
| | Molecular Targeted Therapy | 6 | 2019 | 356 | 1.610 |
Why?
| | Hemangiosarcoma | 2 | 2021 | 19 | 1.430 |
Why?
| | Bone Neoplasms | 7 | 2023 | 199 | 1.330 |
Why?
| | Gastrointestinal Stromal Tumors | 4 | 2022 | 43 | 1.210 |
Why?
| | Biomarkers, Tumor | 8 | 2022 | 1059 | 1.130 |
Why?
| | Antineoplastic Agents | 8 | 2023 | 1974 | 1.080 |
Why?
| | Precision Medicine | 2 | 2019 | 363 | 1.030 |
Why?
| | Circulating Tumor DNA | 2 | 2022 | 22 | 0.890 |
Why?
| | Pyrimidines | 2 | 2018 | 382 | 0.880 |
Why?
| | Leiomyosarcoma | 1 | 2022 | 23 | 0.860 |
Why?
| | Sulfonamides | 2 | 2018 | 445 | 0.860 |
Why?
| | Immunomodulation | 2 | 2019 | 89 | 0.700 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1390 | 0.670 |
Why?
| | Antineoplastic Agents, Immunological | 3 | 2019 | 156 | 0.660 |
Why?
| | Salvage Therapy | 1 | 2019 | 130 | 0.650 |
Why?
| | Neoplasms | 4 | 2023 | 2179 | 0.600 |
Why?
| | DEAD-box RNA Helicases | 1 | 2015 | 56 | 0.520 |
Why?
| | Neovascularization, Pathologic | 1 | 2017 | 287 | 0.510 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2015 | 90 | 0.510 |
Why?
| | Sarcoma, Ewing | 1 | 2015 | 65 | 0.500 |
Why?
| | Chondrosarcoma | 3 | 2023 | 12 | 0.500 |
Why?
| | Solitary Fibrous Tumors | 1 | 2013 | 3 | 0.480 |
Why?
| | Thoracic Neoplasms | 1 | 2013 | 34 | 0.460 |
Why?
| | Prognosis | 7 | 2022 | 3443 | 0.460 |
Why?
| | Humans | 46 | 2023 | 118972 | 0.460 |
Why?
| | Liposarcoma | 2 | 2023 | 26 | 0.440 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 900 | 0.430 |
Why?
| | Giant Cell Tumor of Bone | 2 | 2021 | 6 | 0.400 |
Why?
| | Magnetic Resonance Imaging | 3 | 2021 | 3174 | 0.390 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1022 | 0.390 |
Why?
| | Bone Density Conservation Agents | 2 | 2021 | 61 | 0.380 |
Why?
| | Combined Modality Therapy | 5 | 2019 | 1166 | 0.370 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 2 | 2019 | 41 | 0.320 |
Why?
| | Indazoles | 2 | 2018 | 60 | 0.270 |
Why?
| | Treatment Outcome | 8 | 2021 | 9342 | 0.260 |
Why?
| | Isocitrate Dehydrogenase | 2 | 2015 | 38 | 0.260 |
Why?
| | Liquid Biopsy | 2 | 2022 | 6 | 0.260 |
Why?
| | Denosumab | 2 | 2021 | 7 | 0.250 |
Why?
| | Imidazoles | 2 | 2015 | 232 | 0.240 |
Why?
| | Protein Kinase Inhibitors | 2 | 2021 | 811 | 0.240 |
Why?
| | Adult | 14 | 2023 | 31512 | 0.240 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2023 | 34 | 0.230 |
Why?
| | Cancer Vaccines | 3 | 2019 | 139 | 0.230 |
Why?
| | Tetrahydronaphthalenes | 1 | 2023 | 32 | 0.220 |
Why?
| | Mutation | 4 | 2022 | 3457 | 0.220 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2019 | 667 | 0.220 |
Why?
| | Postoperative Complications | 1 | 2013 | 2235 | 0.220 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 93 | 0.210 |
Why?
| | Survival Rate | 2 | 2019 | 1720 | 0.210 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2019 | 204 | 0.210 |
Why?
| | Giant Cell Tumor of Tendon Sheath | 1 | 2021 | 2 | 0.210 |
Why?
| | Tumor Microenvironment | 3 | 2019 | 454 | 0.200 |
Why?
| | Translocation, Genetic | 2 | 2019 | 92 | 0.200 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2021 | 15 | 0.200 |
Why?
| | Clinical Trials, Phase II as Topic | 3 | 2019 | 57 | 0.200 |
Why?
| | Quinazolines | 1 | 2023 | 245 | 0.200 |
Why?
| | beta Catenin | 1 | 2022 | 219 | 0.190 |
Why?
| | Chromosomes, Human, Pair 7 | 1 | 2019 | 15 | 0.180 |
Why?
| | Osteoblasts | 1 | 2021 | 115 | 0.180 |
Why?
| | Chromosomes, Human, Pair 12 | 1 | 2019 | 28 | 0.180 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2019 | 21 | 0.180 |
Why?
| | Oncogene Fusion | 1 | 2019 | 9 | 0.180 |
Why?
| | Gene Fusion | 1 | 2019 | 18 | 0.180 |
Why?
| | Neoplasm Staging | 4 | 2018 | 1223 | 0.180 |
Why?
| | Sarcoma, Synovial | 1 | 2019 | 10 | 0.180 |
Why?
| | Chemoradiotherapy | 1 | 2021 | 200 | 0.180 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2019 | 86 | 0.180 |
Why?
| | Gene Amplification | 1 | 2019 | 97 | 0.170 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 453 | 0.170 |
Why?
| | Retrospective Studies | 5 | 2022 | 12978 | 0.170 |
Why?
| | Tumor Escape | 1 | 2019 | 38 | 0.170 |
Why?
| | Female | 13 | 2023 | 61564 | 0.170 |
Why?
| | Middle Aged | 10 | 2021 | 27617 | 0.170 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 544 | 0.170 |
Why?
| | Animals | 9 | 2021 | 33381 | 0.170 |
Why?
| | Neurofibrosarcoma | 1 | 2018 | 2 | 0.160 |
Why?
| | Costimulatory and Inhibitory T-Cell Receptors | 1 | 2018 | 8 | 0.160 |
Why?
| | Antigens, Neoplasm | 1 | 2019 | 228 | 0.160 |
Why?
| | Carcinogenesis | 1 | 2019 | 182 | 0.160 |
Why?
| | Male | 12 | 2022 | 57801 | 0.160 |
Why?
| | Hematology | 1 | 2017 | 12 | 0.160 |
Why?
| | Immunotherapy, Adoptive | 1 | 2019 | 191 | 0.150 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2019 | 229 | 0.150 |
Why?
| | Follow-Up Studies | 2 | 2019 | 4596 | 0.150 |
Why?
| | Actins | 1 | 2019 | 404 | 0.150 |
Why?
| | Rhabdoid Tumor | 1 | 2018 | 80 | 0.150 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 736 | 0.150 |
Why?
| | Radiography | 2 | 2021 | 861 | 0.150 |
Why?
| | T-Lymphocyte Subsets | 1 | 2019 | 396 | 0.150 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 969 | 0.140 |
Why?
| | Simulation Training | 1 | 2017 | 66 | 0.140 |
Why?
| | Cell Line, Tumor | 4 | 2015 | 2851 | 0.140 |
Why?
| | Glutarates | 1 | 2015 | 6 | 0.140 |
Why?
| | Drug Discovery | 1 | 2017 | 124 | 0.140 |
Why?
| | Benzeneacetamides | 1 | 2015 | 7 | 0.140 |
Why?
| | Medical Oncology | 1 | 2017 | 229 | 0.130 |
Why?
| | Azepines | 1 | 2015 | 74 | 0.130 |
Why?
| | Drug Monitoring | 1 | 2016 | 187 | 0.130 |
Why?
| | Disease Management | 1 | 2019 | 571 | 0.130 |
Why?
| | Ovarian Neoplasms | 1 | 2019 | 420 | 0.130 |
Why?
| | T-Lymphocytes | 2 | 2019 | 1774 | 0.130 |
Why?
| | Receptor, IGF Type 1 | 1 | 2014 | 59 | 0.130 |
Why?
| | Gene Knockdown Techniques | 1 | 2015 | 311 | 0.120 |
Why?
| | Fellowships and Scholarships | 1 | 2017 | 250 | 0.120 |
Why?
| | Macrophages | 1 | 2021 | 1324 | 0.120 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2014 | 71 | 0.120 |
Why?
| | Aged | 7 | 2021 | 19657 | 0.120 |
Why?
| | Paired Box Transcription Factors | 1 | 2014 | 40 | 0.120 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2017 | 368 | 0.120 |
Why?
| | Chordoma | 1 | 2013 | 13 | 0.120 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 304 | 0.120 |
Why?
| | Benzimidazoles | 1 | 2014 | 140 | 0.120 |
Why?
| | Apoptosis | 3 | 2023 | 2484 | 0.120 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2013 | 78 | 0.120 |
Why?
| | Antibodies, Monoclonal | 2 | 2023 | 1284 | 0.120 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2018 | 671 | 0.120 |
Why?
| | Membrane Proteins | 1 | 2019 | 1055 | 0.110 |
Why?
| | Rhabdomyosarcoma | 1 | 2014 | 57 | 0.110 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2013 | 189 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2015 | 740 | 0.110 |
Why?
| | Forkhead Transcription Factors | 1 | 2014 | 182 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2015 | 1167 | 0.110 |
Why?
| | Disease-Free Survival | 1 | 2014 | 649 | 0.110 |
Why?
| | Young Adult | 6 | 2021 | 10793 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2275 | 0.110 |
Why?
| | Aged, 80 and over | 4 | 2019 | 6561 | 0.110 |
Why?
| | Connective Tissue | 2 | 2022 | 37 | 0.100 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2014 | 181 | 0.100 |
Why?
| | Sirolimus | 1 | 2013 | 195 | 0.100 |
Why?
| | Enzyme Inhibitors | 1 | 2015 | 827 | 0.100 |
Why?
| | Doxorubicin | 1 | 2013 | 302 | 0.100 |
Why?
| | Angiogenesis Inhibitors | 1 | 2013 | 219 | 0.100 |
Why?
| | Curriculum | 1 | 2017 | 910 | 0.100 |
Why?
| | Immunohistochemistry | 3 | 2021 | 1691 | 0.090 |
Why?
| | NF-kappa B | 1 | 2013 | 670 | 0.090 |
Why?
| | Consensus | 2 | 2022 | 534 | 0.090 |
Why?
| | Clinical Trials, Phase I as Topic | 2 | 2019 | 47 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2013 | 1244 | 0.080 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2019 | 112 | 0.080 |
Why?
| | Mice | 4 | 2021 | 15520 | 0.080 |
Why?
| | Neoplasm Grading | 2 | 2018 | 258 | 0.080 |
Why?
| | Adolescent | 4 | 2021 | 18480 | 0.070 |
Why?
| | Cohort Studies | 1 | 2014 | 5116 | 0.060 |
Why?
| | Frameshift Mutation | 1 | 2023 | 28 | 0.060 |
Why?
| | Activating Transcription Factor 4 | 1 | 2023 | 18 | 0.060 |
Why?
| | Proteasome Inhibitors | 1 | 2023 | 44 | 0.060 |
Why?
| | Disease Progression | 2 | 2022 | 2490 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2023 | 65 | 0.060 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2023 | 139 | 0.060 |
Why?
| | Cell Differentiation | 2 | 2021 | 1753 | 0.060 |
Why?
| | Valine | 1 | 2023 | 77 | 0.060 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2023 | 76 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2022 | 89 | 0.050 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2022 | 109 | 0.050 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2023 | 136 | 0.050 |
Why?
| | Cytokines | 2 | 2019 | 1900 | 0.050 |
Why?
| | Prospective Studies | 2 | 2022 | 6471 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2021 | 456 | 0.050 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2019 | 41 | 0.050 |
Why?
| | HLA-A Antigens | 1 | 2019 | 50 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 576 | 0.040 |
Why?
| | Mice, Nude | 1 | 2021 | 663 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2023 | 455 | 0.040 |
Why?
| | Cell Lineage | 1 | 2021 | 318 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2023 | 1687 | 0.040 |
Why?
| | Oncolytic Viruses | 1 | 2018 | 5 | 0.040 |
Why?
| | Oncolytic Virotherapy | 1 | 2018 | 8 | 0.040 |
Why?
| | Organ Sparing Treatments | 1 | 2018 | 31 | 0.040 |
Why?
| | Margins of Excision | 1 | 2018 | 31 | 0.040 |
Why?
| | SMARCB1 Protein | 1 | 2018 | 17 | 0.040 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2018 | 189 | 0.040 |
Why?
| | SEER Program | 1 | 2018 | 205 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 134 | 0.040 |
Why?
| | Syndrome | 1 | 2018 | 344 | 0.040 |
Why?
| | Pedigree | 1 | 2018 | 485 | 0.040 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2017 | 54 | 0.040 |
Why?
| | Models, Molecular | 1 | 2021 | 1435 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 1 | 2021 | 2478 | 0.030 |
Why?
| | Surgical Procedures, Operative | 1 | 2018 | 215 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2019 | 632 | 0.030 |
Why?
| | Immune System | 1 | 2017 | 181 | 0.030 |
Why?
| | Risk | 1 | 2018 | 853 | 0.030 |
Why?
| | Population Surveillance | 1 | 2018 | 413 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2424 | 0.030 |
Why?
| | PAX3 Transcription Factor | 1 | 2014 | 12 | 0.030 |
Why?
| | Forkhead Box Protein O1 | 1 | 2014 | 15 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2021 | 2275 | 0.030 |
Why?
| | Radiation | 1 | 2014 | 26 | 0.030 |
Why?
| | Cell Cycle Checkpoints | 1 | 2014 | 87 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2015 | 300 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2013 | 194 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2017 | 399 | 0.030 |
Why?
| | Chondrocytes | 1 | 2015 | 206 | 0.030 |
Why?
| | Program Evaluation | 1 | 2017 | 845 | 0.030 |
Why?
| | Rats | 1 | 2021 | 5392 | 0.030 |
Why?
| | Quality of Life | 1 | 2023 | 2366 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2021 | 3730 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1795 | 0.030 |
Why?
| | Communication | 1 | 2017 | 761 | 0.030 |
Why?
| | Phenotype | 1 | 2019 | 3003 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1012 | 0.020 |
Why?
| | Recurrence | 1 | 2013 | 975 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 502 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 3588 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1185 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 2874 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2013 | 1945 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1882 | 0.020 |
Why?
| | Child | 2 | 2019 | 19129 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2013 | 1597 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2062 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 4708 | 0.020 |
Why?
| | Child, Preschool | 1 | 2019 | 9491 | 0.020 |
Why?
| | Infant | 1 | 2018 | 8293 | 0.020 |
Why?
|
|
Wilky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|